From fungus fighter to cancer slayer: itraconazole as a multifaceted candidate for drug-resistant prostate cancer [0.03%]
从抗真菌到抗癌：特拉康唑作为耐药前列腺癌的多面型候选药物
Luciano O Souza,Despoina G Papoutsi,José M A Moreira
Luciano O Souza
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease state with limited durable responses to existing therapies, including taxane-based chemotherapy. Resistance mechanisms are multi...
Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer [0.03%]
转移性雄激素通路调节剂敏感型前列腺癌男性患者对雄激素受体途径抑制剂产生非同寻常的疗效和耐药性的临床及基因组决定因素
Jane McKenzie,Lauren Howard,Joseph J Park et al.
Jane McKenzie et al.
Background: Identifying clinical and genomic predictors of response to androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) for metastatic androgen pathway modulator sensitive (APMS) prostate...
Germline genetic risk and prostate cancer-specific mortality in a population-based incident cohort [0.03%]
基于人群的前列腺癌患者遗传风险基因组与癌症特异性死亡率之间的关系研究
Lucy Lu,Julian Xu,Zhuqing Shi et al.
Lucy Lu et al.
Background: Multiple germline variants are associated with prostate cancer (PCa) susceptibility and aggressive features; however, their value for predicting prostate cancer-specific mortality (PCSM) at the time of diagnos...
Counseling is counseling is counseling is counseling - The evolution of LUTS/BPO care [0.03%]
咨询就是咨询就是咨询就是咨询-LUTS/BPH诊治的变迁
Mattia Sibona,Wayne Kuang,Paolo Gontero et al.
Mattia Sibona et al.
Prognostic value of cribriform pattern and intraductal carcinoma of the prostate after radical prostatectomy: A systematic review and meta-analysis using contemporary consensus recommendations [0.03%]
基于当代共识推荐的根治术后筛状模式和导管内癌前列腺预后价值的系统评价和meta分析研究
Francesco Ditonno,Alessandro Veccia,Rui M Bernardino et al.
Francesco Ditonno et al.
Background: Cribriform pattern (CP) and intraductal carcinoma of the prostate (IDC-P) are recognised as adverse histopathological markers. However, their precise prognostic weight in the post-radical prostatectomy (RP) se...
Long-term oncologic outcomes of patients with grade group 1 prostate cancer and pT3a disease on final pathology [0.03%]
最终病理检查为前列腺癌分级组1期伴pT3a疾病的患者的长期肿瘤结局
Mohamad Watfa,Kristina Dortche,Gagan Fervaha et al.
Mohamad Watfa et al.
Background: Grade Group 1 (GG1) prostate cancer is biologically indolent and typically managed with active surveillance (AS), yet pT3a pathology is occasionally identified at radical prostatectomy (RP). Its prognostic sig...
No racial disparities in prostate cancer-specific mortality after biochemical recurrence following radical prostatectomy or radiation therapy [0.03%]
前列腺切除或放疗后生化复发的前列腺癌特异性死亡率无种族差异
Carlo Silvani,Alfonso Santangelo,Alex Stephens et al.
Carlo Silvani et al.
Background: Racial disparities in prostate cancer are well-documented, with Black men experiencing twice the mortality of White men. While prior studies suggest these disparities reflect inequitable access rather than bio...
Focal therapy for localized prostate cancer: not all that glitters is gold [0.03%]
局部前列腺癌的焦点治疗：闪光点与隐患
Antonio Franco,Jean de la Rosette,Cosimo De Nunzio
Antonio Franco
A nationwide histopathology study reflecting the impact of the introduction of MRI in the diagnostic trajectory of prostate cancer in routine clinical care [0.03%]
一项全国性病理学研究报告了MRI在前列腺癌诊断过程中的影响及临床应用情况
Anne M A Prinsen,Stefan Slagter,Ivo G Schoots et al.
Anne M A Prinsen et al.
Background: Magnetic resonance imaging (MRI), introduced into European (2019) and Dutch (2020) guidelines, reshaped prostate cancer (PCa) diagnostics by altering biopsy indications and strategies. In expert-center studies...
Mahmoud Laymon,Yahya H Elmorsy,Ahmed M Elshal et al.
Mahmoud Laymon et al.